Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 55 | 2023 | 4808 | 2.900 |
Why?
|
Endometrial Neoplasms | 10 | 2021 | 1359 | 1.160 |
Why?
|
Peritoneal Neoplasms | 11 | 2023 | 700 | 1.080 |
Why?
|
Neoplastic Syndromes, Hereditary | 2 | 2019 | 239 | 0.960 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 33 | 2020 | 11603 | 0.940 |
Why?
|
Genital Neoplasms, Female | 5 | 2023 | 525 | 0.860 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2020 | 9207 | 0.840 |
Why?
|
Taxoids | 10 | 2013 | 667 | 0.780 |
Why?
|
Paclitaxel | 20 | 2014 | 1702 | 0.730 |
Why?
|
Gynecologic Surgical Procedures | 5 | 2014 | 302 | 0.680 |
Why?
|
Diaphragm | 5 | 2013 | 351 | 0.670 |
Why?
|
Vulvar Neoplasms | 4 | 2022 | 264 | 0.600 |
Why?
|
Neoplasms, Glandular and Epithelial | 6 | 2015 | 484 | 0.550 |
Why?
|
Antineoplastic Agents, Phytogenic | 6 | 2000 | 610 | 0.500 |
Why?
|
Pelvic Exenteration | 3 | 2014 | 21 | 0.500 |
Why?
|
Cystadenocarcinoma, Serous | 3 | 2024 | 458 | 0.490 |
Why?
|
Antineoplastic Agents | 22 | 2016 | 13558 | 0.480 |
Why?
|
Camptothecin | 3 | 2004 | 580 | 0.470 |
Why?
|
Neoplasm Staging | 29 | 2023 | 11067 | 0.450 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 254 | 0.440 |
Why?
|
Neoplasm, Residual | 4 | 2014 | 994 | 0.440 |
Why?
|
Angiogenesis Inhibitors | 4 | 2015 | 2036 | 0.440 |
Why?
|
Uterine Cervical Neoplasms | 8 | 2020 | 1992 | 0.400 |
Why?
|
Laparotomy | 2 | 2016 | 458 | 0.360 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2791 | 0.350 |
Why?
|
Carboplatin | 11 | 2014 | 790 | 0.350 |
Why?
|
Fallopian Tube Neoplasms | 6 | 2011 | 326 | 0.340 |
Why?
|
Drug Administration Schedule | 21 | 2013 | 4883 | 0.330 |
Why?
|
Lymph Node Excision | 7 | 2022 | 1290 | 0.320 |
Why?
|
Female | 117 | 2024 | 386339 | 0.310 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 1097 | 0.300 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 1863 | 0.300 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2001 | 5215 | 0.300 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2783 | 0.300 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 17650 | 0.290 |
Why?
|
Dacarbazine | 2 | 2006 | 560 | 0.280 |
Why?
|
Uterine Neoplasms | 3 | 2024 | 1445 | 0.280 |
Why?
|
Hysterectomy | 5 | 2021 | 896 | 0.280 |
Why?
|
Middle Aged | 86 | 2021 | 217250 | 0.280 |
Why?
|
Aged | 77 | 2021 | 166705 | 0.270 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5598 | 0.270 |
Why?
|
Mixed Tumor, Mullerian | 1 | 2006 | 56 | 0.270 |
Why?
|
Phosphorylcholine | 1 | 2006 | 153 | 0.270 |
Why?
|
Carcinoma, Endometrioid | 2 | 2021 | 277 | 0.260 |
Why?
|
Muscle Neoplasms | 1 | 2006 | 131 | 0.260 |
Why?
|
Disease-Free Survival | 15 | 2015 | 6791 | 0.250 |
Why?
|
Abdominal Fat | 1 | 2007 | 223 | 0.250 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3163 | 0.250 |
Why?
|
Pleural Effusion | 2 | 2013 | 336 | 0.240 |
Why?
|
Adult | 75 | 2021 | 217168 | 0.230 |
Why?
|
Combined Modality Therapy | 13 | 2014 | 8549 | 0.230 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2006 | 617 | 0.230 |
Why?
|
Leiomyosarcoma | 2 | 2021 | 426 | 0.230 |
Why?
|
Anthraquinones | 2 | 1993 | 38 | 0.230 |
Why?
|
Infusions, Intravenous | 10 | 2011 | 2224 | 0.220 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2023 | 57 | 0.220 |
Why?
|
Humans | 123 | 2024 | 752810 | 0.220 |
Why?
|
Guanine | 2 | 2001 | 276 | 0.210 |
Why?
|
Lung Neoplasms | 14 | 2001 | 13173 | 0.210 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2000 | 672 | 0.210 |
Why?
|
Ovariectomy | 3 | 2014 | 610 | 0.210 |
Why?
|
Immunotherapy | 1 | 2018 | 4601 | 0.210 |
Why?
|
Survival Rate | 18 | 2018 | 12751 | 0.200 |
Why?
|
Galectin 3 | 1 | 2024 | 240 | 0.200 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2024 | 656 | 0.180 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2022 | 720 | 0.180 |
Why?
|
Topotecan | 6 | 2013 | 132 | 0.180 |
Why?
|
Cisplatin | 9 | 2013 | 1646 | 0.180 |
Why?
|
Doxorubicin | 3 | 2012 | 2193 | 0.180 |
Why?
|
Deoxycytidine | 4 | 2014 | 859 | 0.170 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2020 | 45 | 0.170 |
Why?
|
Receptors, Growth Factor | 1 | 2001 | 324 | 0.170 |
Why?
|
Interferon-alpha | 4 | 2000 | 914 | 0.170 |
Why?
|
Phenyl Ethers | 1 | 1999 | 62 | 0.170 |
Why?
|
Melanoma | 1 | 2018 | 5620 | 0.170 |
Why?
|
Lymph Nodes | 3 | 2022 | 3474 | 0.170 |
Why?
|
Histamine Antagonists | 1 | 1999 | 92 | 0.170 |
Why?
|
Sarcoma | 2 | 2006 | 1789 | 0.160 |
Why?
|
Ifosfamide | 4 | 1998 | 232 | 0.160 |
Why?
|
Blood Proteins | 1 | 2024 | 1155 | 0.160 |
Why?
|
Aged, 80 and over | 22 | 2021 | 58347 | 0.160 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2021 | 352 | 0.160 |
Why?
|
Organoplatinum Compounds | 4 | 2010 | 405 | 0.150 |
Why?
|
Neoplasms | 8 | 2006 | 21810 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2001 | 626 | 0.150 |
Why?
|
Treatment Outcome | 30 | 2020 | 64288 | 0.150 |
Why?
|
Tretinoin | 1 | 2000 | 520 | 0.150 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 874 | 0.150 |
Why?
|
Canada | 8 | 2006 | 2104 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2013 | 5164 | 0.150 |
Why?
|
Depsipeptides | 1 | 1998 | 94 | 0.150 |
Why?
|
Ontario | 1 | 2018 | 394 | 0.150 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1999 | 346 | 0.140 |
Why?
|
Robotics | 2 | 2015 | 877 | 0.140 |
Why?
|
Medical Oncology | 2 | 2016 | 2284 | 0.140 |
Why?
|
Drug Discovery | 1 | 2024 | 1057 | 0.130 |
Why?
|
Genetic Counseling | 1 | 2020 | 616 | 0.130 |
Why?
|
Obesity, Morbid | 1 | 2007 | 1255 | 0.130 |
Why?
|
Survival Analysis | 9 | 2012 | 10187 | 0.130 |
Why?
|
Aminoquinolines | 1 | 2016 | 109 | 0.130 |
Why?
|
Leiomyoma | 1 | 2021 | 665 | 0.130 |
Why?
|
Paget Disease, Extramammary | 1 | 2016 | 47 | 0.130 |
Why?
|
Leukemia, Myeloid | 1 | 1999 | 696 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2011 | 10798 | 0.130 |
Why?
|
Retrospective Studies | 23 | 2023 | 79160 | 0.130 |
Why?
|
Peptides, Cyclic | 1 | 1998 | 393 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 638 | 0.130 |
Why?
|
Laparoscopy | 1 | 2007 | 2132 | 0.120 |
Why?
|
DNA Repair | 1 | 2024 | 2023 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2021 | 969 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2001 | 2353 | 0.120 |
Why?
|
New York City | 2 | 2006 | 712 | 0.110 |
Why?
|
Vaginal Neoplasms | 1 | 2014 | 105 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 935 | 0.110 |
Why?
|
Aminoglycosides | 1 | 1994 | 163 | 0.110 |
Why?
|
Social Support | 1 | 2023 | 2118 | 0.110 |
Why?
|
Histone Deacetylase 1 | 1 | 2013 | 132 | 0.110 |
Why?
|
Pyrazoles | 2 | 1993 | 1988 | 0.110 |
Why?
|
Benzhydryl Compounds | 1 | 1999 | 933 | 0.110 |
Why?
|
Agranulocytosis | 3 | 2000 | 99 | 0.110 |
Why?
|
Parity | 1 | 2016 | 921 | 0.100 |
Why?
|
Piperidones | 1 | 2012 | 37 | 0.100 |
Why?
|
Perioperative Care | 1 | 2020 | 1015 | 0.100 |
Why?
|
Colostomy | 1 | 2012 | 103 | 0.100 |
Why?
|
BRCA1 Protein | 2 | 2024 | 1129 | 0.100 |
Why?
|
Prognosis | 7 | 2024 | 29369 | 0.100 |
Why?
|
Psychometrics | 1 | 2021 | 3008 | 0.100 |
Why?
|
Urinary Diversion | 1 | 2012 | 135 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2000 | 1573 | 0.100 |
Why?
|
Astrocytoma | 1 | 1996 | 777 | 0.090 |
Why?
|
Reproduction | 1 | 2016 | 643 | 0.090 |
Why?
|
Carcinoma | 2 | 2001 | 2341 | 0.090 |
Why?
|
Fertility | 1 | 2016 | 773 | 0.090 |
Why?
|
Pentostatin | 2 | 2000 | 26 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2014 | 759 | 0.090 |
Why?
|
Splenectomy | 2 | 2008 | 389 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3586 | 0.090 |
Why?
|
Leukemia, Hairy Cell | 2 | 2000 | 83 | 0.090 |
Why?
|
Isoxazoles | 3 | 1990 | 227 | 0.090 |
Why?
|
Documentation | 1 | 2016 | 879 | 0.080 |
Why?
|
Palliative Care | 4 | 2018 | 3578 | 0.080 |
Why?
|
Breast Neoplasms | 5 | 2006 | 20844 | 0.080 |
Why?
|
Feasibility Studies | 4 | 2014 | 5144 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2023 | 3489 | 0.080 |
Why?
|
Intestinal Obstruction | 1 | 2013 | 435 | 0.080 |
Why?
|
Glutamates | 2 | 2001 | 390 | 0.080 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2013 | 341 | 0.080 |
Why?
|
Injections, Intravenous | 5 | 2006 | 1380 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1648 | 0.080 |
Why?
|
CA-125 Antigen | 2 | 2009 | 276 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2016 | 39089 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2014 | 6482 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2035 | 0.080 |
Why?
|
Prospective Studies | 10 | 2023 | 53833 | 0.080 |
Why?
|
Quality of Life | 9 | 2023 | 13162 | 0.080 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 870 | 0.080 |
Why?
|
Carcinoma, Small Cell | 3 | 1999 | 415 | 0.080 |
Why?
|
Etoposide | 3 | 1999 | 625 | 0.080 |
Why?
|
Pancreatic Fistula | 1 | 2008 | 147 | 0.070 |
Why?
|
Decompression, Surgical | 1 | 2013 | 595 | 0.070 |
Why?
|
Disease Progression | 6 | 2013 | 13403 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3302 | 0.070 |
Why?
|
Kidney Neoplasms | 3 | 2000 | 4273 | 0.070 |
Why?
|
Pancreatectomy | 2 | 2008 | 807 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 2 | 2000 | 3176 | 0.070 |
Why?
|
Databases, Factual | 3 | 2008 | 7899 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2006 | 4863 | 0.070 |
Why?
|
Anxiety | 1 | 2021 | 4456 | 0.070 |
Why?
|
Referral and Consultation | 2 | 2020 | 3560 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4006 | 0.070 |
Why?
|
Abdominal Neoplasms | 1 | 2008 | 285 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1406 | 0.070 |
Why?
|
Omentum | 1 | 2007 | 168 | 0.070 |
Why?
|
Oxazoles | 2 | 1986 | 197 | 0.070 |
Why?
|
Male | 31 | 2018 | 355160 | 0.070 |
Why?
|
Carmustine | 1 | 2006 | 137 | 0.070 |
Why?
|
Remission Induction | 4 | 2000 | 2372 | 0.070 |
Why?
|
Young Adult | 6 | 2021 | 57732 | 0.070 |
Why?
|
Brain Neoplasms | 3 | 1996 | 8895 | 0.070 |
Why?
|
Infusions, Parenteral | 3 | 2006 | 402 | 0.070 |
Why?
|
Lymphatic Metastasis | 3 | 2022 | 2925 | 0.060 |
Why?
|
Abdomen | 2 | 2008 | 1112 | 0.060 |
Why?
|
Nomograms | 1 | 2007 | 238 | 0.060 |
Why?
|
Pain, Postoperative | 1 | 2016 | 1671 | 0.060 |
Why?
|
Peritoneum | 1 | 2006 | 221 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 2 | 2016 | 4483 | 0.060 |
Why?
|
Academies and Institutes | 1 | 2006 | 316 | 0.060 |
Why?
|
Platinum Compounds | 2 | 2009 | 93 | 0.060 |
Why?
|
DNA Damage | 1 | 2013 | 2408 | 0.060 |
Why?
|
Cohort Studies | 6 | 2022 | 40996 | 0.060 |
Why?
|
Postoperative Care | 2 | 2007 | 1465 | 0.060 |
Why?
|
Neutropenia | 4 | 2000 | 884 | 0.060 |
Why?
|
Rad51 Recombinase | 1 | 2024 | 186 | 0.060 |
Why?
|
Half-Life | 1 | 2004 | 647 | 0.050 |
Why?
|
Drug Evaluation | 6 | 1992 | 642 | 0.050 |
Why?
|
Glioblastoma | 2 | 1996 | 3473 | 0.050 |
Why?
|
Thionucleotides | 1 | 2003 | 113 | 0.050 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 58 | 0.050 |
Why?
|
Length of Stay | 2 | 2015 | 6372 | 0.050 |
Why?
|
Inpatients | 1 | 2015 | 2560 | 0.050 |
Why?
|
Prevalence | 1 | 2019 | 15505 | 0.050 |
Why?
|
Medical Records | 1 | 2007 | 1401 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6503 | 0.050 |
Why?
|
Nausea | 3 | 2000 | 672 | 0.050 |
Why?
|
Folic Acid Antagonists | 1 | 2001 | 76 | 0.050 |
Why?
|
Galectins | 1 | 2024 | 281 | 0.050 |
Why?
|
Glioma | 1 | 1996 | 3394 | 0.050 |
Why?
|
Soft Tissue Neoplasms | 1 | 1989 | 1149 | 0.050 |
Why?
|
Liposomes | 1 | 2004 | 772 | 0.050 |
Why?
|
Endometrial Hyperplasia | 1 | 2021 | 98 | 0.050 |
Why?
|
Colorectal Neoplasms | 2 | 2006 | 6793 | 0.040 |
Why?
|
Area Under Curve | 1 | 2004 | 1614 | 0.040 |
Why?
|
Spleen | 1 | 2006 | 2276 | 0.040 |
Why?
|
Amifostine | 1 | 1999 | 40 | 0.040 |
Why?
|
Fever | 2 | 2013 | 1613 | 0.040 |
Why?
|
Analgesics, Opioid | 1 | 2016 | 3688 | 0.040 |
Why?
|
Apoptosis | 2 | 2013 | 9436 | 0.040 |
Why?
|
Pancreas | 1 | 2006 | 1676 | 0.040 |
Why?
|
Radiation-Protective Agents | 1 | 1999 | 88 | 0.040 |
Why?
|
Patient Selection | 2 | 2015 | 4239 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2024 | 590 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2021 | 219 | 0.040 |
Why?
|
Administration, Oral | 2 | 2006 | 4002 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2006 | 1268 | 0.040 |
Why?
|
Nitriles | 1 | 2004 | 956 | 0.040 |
Why?
|
Epirubicin | 2 | 2012 | 82 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2016 | 7814 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2024 | 3079 | 0.040 |
Why?
|
Triazoles | 1 | 2004 | 906 | 0.040 |
Why?
|
United States | 6 | 2023 | 71434 | 0.040 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1999 | 121 | 0.040 |
Why?
|
Recombinant Proteins | 5 | 2000 | 6513 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 376 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2017 | 65 | 0.040 |
Why?
|
Quality Indicators, Health Care | 1 | 2007 | 1810 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 16739 | 0.040 |
Why?
|
Diphenhydramine | 1 | 1996 | 63 | 0.030 |
Why?
|
Drug Synergism | 1 | 2000 | 1734 | 0.030 |
Why?
|
Postoperative Period | 2 | 2013 | 1806 | 0.030 |
Why?
|
Fatigue | 2 | 2000 | 1523 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9554 | 0.030 |
Why?
|
Risk Factors | 3 | 2019 | 73418 | 0.030 |
Why?
|
Antiemetics | 1 | 1998 | 185 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2013 | 1773 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 173 | 0.030 |
Why?
|
Granulocytes | 1 | 1998 | 551 | 0.030 |
Why?
|
Paresthesia | 1 | 1996 | 162 | 0.030 |
Why?
|
Neoplasms, Second Primary | 2 | 2000 | 1052 | 0.030 |
Why?
|
Rectal Neoplasms | 1 | 1984 | 1145 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 794 | 0.030 |
Why?
|
Ethics, Medical | 1 | 2001 | 788 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2017 | 10200 | 0.030 |
Why?
|
Hematuria | 1 | 1996 | 233 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 1994 | 7294 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 6964 | 0.030 |
Why?
|
Drug Tolerance | 1 | 1996 | 370 | 0.030 |
Why?
|
Nephrectomy | 1 | 2000 | 1000 | 0.030 |
Why?
|
Confusion | 1 | 1996 | 273 | 0.030 |
Why?
|
Treatment Failure | 1 | 2000 | 2635 | 0.030 |
Why?
|
Liver | 2 | 2008 | 7427 | 0.030 |
Why?
|
Risk Assessment | 1 | 2016 | 23785 | 0.030 |
Why?
|
Models, Molecular | 1 | 2024 | 5401 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 693 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 29427 | 0.030 |
Why?
|
Diarrhea | 1 | 2000 | 1335 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2010 | 21857 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2005 | 7997 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 851 | 0.030 |
Why?
|
Thoracostomy | 1 | 2013 | 72 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2024 | 10358 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1618 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2001 | 1716 | 0.030 |
Why?
|
Cyclic S-Oxides | 1 | 2012 | 25 | 0.030 |
Why?
|
Hematologic Tests | 1 | 1993 | 236 | 0.030 |
Why?
|
Isotretinoin | 1 | 1994 | 131 | 0.030 |
Why?
|
Arthralgia | 1 | 1996 | 453 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 1984 | 2503 | 0.030 |
Why?
|
Muscular Diseases | 1 | 1996 | 543 | 0.030 |
Why?
|
Interleukin-3 | 1 | 1993 | 421 | 0.030 |
Why?
|
Forecasting | 2 | 2005 | 2917 | 0.030 |
Why?
|
Postoperative Complications | 3 | 2016 | 15438 | 0.030 |
Why?
|
Parenteral Nutrition, Total | 1 | 2013 | 303 | 0.020 |
Why?
|
Cell Movement | 1 | 2024 | 5174 | 0.020 |
Why?
|
Chemokines | 1 | 2016 | 956 | 0.020 |
Why?
|
Ribavirin | 1 | 1993 | 395 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2001 | 2691 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2016 | 1026 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 2013 | 2202 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2012 | 453 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18302 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2012 | 2440 | 0.020 |
Why?
|
Government Agencies | 1 | 1990 | 162 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1994 | 638 | 0.020 |
Why?
|
Sulfonylurea Compounds | 1 | 1992 | 220 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7214 | 0.020 |
Why?
|
Urinary Tract | 1 | 2013 | 309 | 0.020 |
Why?
|
Pilot Projects | 2 | 2016 | 8449 | 0.020 |
Why?
|
Drug Design | 1 | 2015 | 1057 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 717 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2479 | 0.020 |
Why?
|
Hematologic Diseases | 3 | 1996 | 498 | 0.020 |
Why?
|
Dexamethasone | 1 | 1996 | 1923 | 0.020 |
Why?
|
Drug Hypersensitivity | 1 | 1998 | 901 | 0.020 |
Why?
|
Amylases | 1 | 2008 | 169 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8706 | 0.020 |
Why?
|
Bone Marrow | 1 | 1999 | 2907 | 0.020 |
Why?
|
Pain | 2 | 2000 | 5011 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4573 | 0.020 |
Why?
|
Genomics | 1 | 2024 | 5728 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 2008 | 141 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1991 | 882 | 0.020 |
Why?
|
Acute Disease | 1 | 1999 | 7217 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5035 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6137 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12455 | 0.020 |
Why?
|
Incidence | 1 | 2006 | 21162 | 0.020 |
Why?
|
BRCA2 Protein | 1 | 2012 | 788 | 0.020 |
Why?
|
Oncology Service, Hospital | 1 | 2007 | 56 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4071 | 0.020 |
Why?
|
Vomiting | 2 | 2000 | 634 | 0.020 |
Why?
|
Time Factors | 2 | 2009 | 39885 | 0.020 |
Why?
|
Ascites | 1 | 2008 | 338 | 0.020 |
Why?
|
Outpatients | 1 | 2015 | 1575 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 2910 | 0.020 |
Why?
|
Second-Look Surgery | 1 | 2006 | 27 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2012 | 1179 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12918 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5783 | 0.020 |
Why?
|
Animals | 3 | 2024 | 166825 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2900 | 0.020 |
Why?
|
Research Design | 1 | 2001 | 6118 | 0.020 |
Why?
|
Adenocarcinoma | 2 | 2017 | 6308 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2624 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2012 | 2088 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2013 | 4218 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2015 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 1953 | 0.010 |
Why?
|
Genes, bcl-2 | 1 | 2004 | 120 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2004 | 162 | 0.010 |
Why?
|
Epithelial Cells | 2 | 2006 | 3672 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1689 | 0.010 |
Why?
|
Risk Adjustment | 1 | 2007 | 598 | 0.010 |
Why?
|
Histones | 1 | 2013 | 2566 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3427 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 2011 | 9107 | 0.010 |
Why?
|
Drainage | 1 | 2008 | 1154 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 2662 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1990 | 1169 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2004 | 419 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5775 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5780 | 0.010 |
Why?
|
Patient Compliance | 1 | 2012 | 2680 | 0.010 |
Why?
|
Physical Examination | 1 | 2007 | 1236 | 0.010 |
Why?
|
Phosphorylation | 1 | 2012 | 8314 | 0.010 |
Why?
|
Brachytherapy | 1 | 2008 | 1241 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12737 | 0.010 |
Why?
|
Cladribine | 1 | 2000 | 36 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1992 | 4343 | 0.010 |
Why?
|
Medication Adherence | 1 | 2012 | 2133 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 1984 | 519 | 0.010 |
Why?
|
Platelet Count | 2 | 1993 | 774 | 0.010 |
Why?
|
Patient Readmission | 1 | 2013 | 3288 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2013 | 20350 | 0.010 |
Why?
|
Survivors | 1 | 2009 | 2330 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2004 | 1114 | 0.010 |
Why?
|
Adolescent | 3 | 1998 | 86822 | 0.010 |
Why?
|
Models, Biological | 1 | 1993 | 9448 | 0.010 |
Why?
|
Body Mass Index | 1 | 2015 | 12794 | 0.010 |
Why?
|
Mice | 1 | 2024 | 80551 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 6472 | 0.010 |
Why?
|
Cough | 1 | 2000 | 596 | 0.010 |
Why?
|
Epithelium | 1 | 2000 | 1606 | 0.010 |
Why?
|
Lymphopenia | 1 | 1997 | 289 | 0.010 |
Why?
|
Postmenopause | 1 | 2004 | 2493 | 0.010 |
Why?
|
Kidney | 1 | 1990 | 6985 | 0.010 |
Why?
|
Alopecia | 1 | 1999 | 413 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2004 | 2796 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36038 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2004 | 2895 | 0.010 |
Why?
|
Mood Disorders | 1 | 2000 | 1109 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15146 | 0.010 |
Why?
|
Dyspnea | 1 | 2000 | 1347 | 0.010 |
Why?
|
Premedication | 1 | 1993 | 254 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2007 | 4343 | 0.010 |
Why?
|
Platinum | 1 | 1993 | 223 | 0.010 |
Why?
|
Neutrophils | 2 | 1993 | 3726 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3685 | 0.010 |
Why?
|
Leukopenia | 1 | 1988 | 211 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1991 | 1590 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2000 | 14323 | 0.000 |
Why?
|
Heart Rate | 1 | 1993 | 4096 | 0.000 |
Why?
|
Blood Pressure | 1 | 1993 | 8468 | 0.000 |
Why?
|
Cognition Disorders | 1 | 1986 | 3974 | 0.000 |
Why?
|